• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic

Medtronic launches ‘smart’ insulin pen

November 12, 2020 By Nancy Crotti

Medtronic (NYSE:MDT) today announced the launch of its InPen “smart” insulin pen integrated with real-time Guardian Connect continuous glucose monitor (CGM) data. The Fridley, Minn.-based medtech giant is touting InPen as the first and only FDA-cleared smart insulin pen on the market for people on multiple daily insulin injections. The system is designed to provide real-time […]

Filed Under: Diabetes, Featured Tagged With: Companion Medical, Medtronic

Medtronic must face infusion pump lawsuit

November 3, 2020 By Nancy Crotti

Medtronic Synchromed II pain pump

A federal judge in Missouri has blocked an effort by Medtronic (NYSE:MDT) to dismiss a lawsuit alleging that the failure of one of its infusion pumps caused “severe and permanent injuries.” Plaintiff Carissa Sullivan, who has cerebral palsy and spastic quadriplegia, claims that the SynchroMed II infusion pump she had implanted in 2011 failed in 2015, causing […]

Filed Under: Drug-Device Combinations, Featured Tagged With: Medtronic

Study: Medtronic’s drug-coated balloon reduces dialysis interruptions

August 26, 2020 By Nancy Crotti

Medtronic (NYSE:MDT) recently announced the results of a study showing that some kidney disease patients who had a drug-coated balloon (DCB) implanted to treat arteriovenous (AV) failure experienced fewer interruptions of dialysis treatment. Many end-stage renal disease (ESRD) patients require AV fistulae in order to receive continuous dialysis. Blood vessels that feed the access site can […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Medtronic, New England Journal of Medicine

Medtronic to acquire Companion Medical, expands diabetes business

August 11, 2020 By Danielle Kirsh

Medtronic logo updated

Medtronic (NYSE:MDT) today said it would acquire insulin pen manufacturer Companion Medical for an undisclosed amount. Companion Medical’s product portfolio includes the InPen FDA-cleared smart insulin pen system that is paired with an integrated diabetes management app on the market. It is designed to help calculate insulin doses, track active insulin and send reports to caregivers […]

Filed Under: Diabetes, Featured Tagged With: Companion Medical, Medtronic

Medtech manufacturers must add warning label to drug-eluting PAD devices

June 16, 2020 By Nancy Crotti

UK medtech regulators on Monday announced that manufacturers of paclitaxel-eluting balloons for use in peripheral arteries must add a warning label about the devices’ risks. A meta-analysis published in the Journal of the American Heart Association in 2018 suggested that patients treated with paclitaxel-coated balloons and stents for peripheral artery disease could be at a higher risk for late death compared […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance, Vascular Tagged With: B. Braun Medical, Biosensors International, Biotronik, Boston Scientific, cook medical, FDA, Lutonix, LVD Biotech, Medtronic, Spectranetics, UK Medicines and Healthcare products Regulatory Agency

Abbott, Medtronic go head-to-head at ADA conference

June 15, 2020 By Nancy Crotti

Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology. The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller […]

Filed Under: Auto-injectors, Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Research & Development Tagged With: abbott, American Diabetes Association, Centers for Medicare and Medicaid Services (CMS), dariohealth, Medtronic, One Drop, Tandem Diabetes Care

Medtronic touts results of latest MiniMed studies at ADA

June 12, 2020 By Nancy Crotti

Medtronic logo updated

The latest generation of the Medtronic (NYSE:MDT) MiniMed insulin pump met both safety and glycemic endpoints in a study presented today at the American Diabetes Association’s virtual annual conference. The MiniMed 780G closed-loop system is indicated for treating Type 1 diabetes in people aged 7 to 80 years old. It is designed to automate the delivery of […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: American Diabetes Association, Medtronic

Medtronic lands CE Mark for MiniMed 780G insulin pump

June 11, 2020 By Sean Whooley

Medtronic logo updated

Medtronic (NYSE:MDT) announced today that it received CE Mark approval in Europe for its MiniMed 790G next-generation insulin pump. The closed-loop insulin pump system is indicated for treating Type 1 diabetes in people aged 70 to 80 years old. It uses Medtronic’s SmartGuard algorithm to automate the delivery of basal insulin and correction boluses every five […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Regulatory/Compliance Tagged With: Medtronic

FDA says Medtronic MiniMed insulin pump recall is serious

February 12, 2020 By Chris Newmarker

Medtronic Minimed 630g

The U.S. FDA has designated a recall of hundreds of thousands of Medtronic Minimed insulin pumps as Class I — the most serious type of recall. Medtronic (NYSE:MDT) first warned of safety problems with the pumps in November. The recall involves 322,005 pumps — MiniMed 630G (model MMT-1715) and MiniMed 670G (model MMT-1780) — in the […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Recalls Tagged With: insulin, Medtronic

Study: High- and low-dose drug-coated balloons equally effective in PAD

January 30, 2020 By Nancy Crotti

Medtronic, Boston Scientific

A Boston Scientific (NYSE:BSX) device coated with less of the controversial drug paclitaxel than one made by Medtronic (NYSE:MDT) is just as safe and effective for patients with peripheral artery disease (PAD), according to a study published this week. The prospective, randomized controlled trial compared the lower-dose (2 μg/mm2 of paclitaxel) Boston Scientific Ranger drug-coated […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: Boston Scientific, Medtronic

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 15
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS